Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Fr | Galera Therapeutics, Inc. - NT 10-Q, Notification of inability to timely file Form 10-Q or 10-QSB | 1 | SEC Filings | ||
18.10. | Galera Therapeutics, Inc. - 8-K, Current Report | 8 | SEC Filings | ||
06.09. | NSE - Galera Therapeutics, Inc. - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities | 4 | SEC Filings | ||
04.09. | Delisting of Securities of Liberty Resources Acquisition Corp.; Achari Ventures Holdings Corp. I; PetVivo Holdings, Inc.; Galera Therapeutics, Inc.; Clean Energy Special Situations Corp.; Capitalworks Emerging Markets Acquisition ... | 76 | GlobeNewswire (Europe) | NEW YORK, Sept. 04, 2024 (GLOBE NEWSWIRE) -- The Nasdaq Stock Market announced today that it will delist the common stock, units, and warrants of Liberty Resources Acquisition Corp. Liberty Resources... ► Artikel lesen | |
04.09. | Galera Therapeutics, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
14.08. | Galera Therapeutics plans to dissolve and liquidate assets | 5 | Investing.com | ||
14.08. | Galera Therapeutics, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
14.08. | Galera Therapeutics: Galera Announces Board Approval of Complete Liquidation and Dissolution | 151 | GlobeNewswire (Europe) | MALVERN, Pa., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company historically focused on developing a pipeline of novel, proprietary... ► Artikel lesen | |
GALERA THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
08.08. | Galera Therapeutics, Inc. - 8-K, Current Report | 4 | SEC Filings | ||
03.06. | Why Galera Therapeutics (GRTX) Stock Is Nosediving | 12 | Benzinga.com | ||
03.06. | Galera Therapeutics, Inc. - 8-K, Current Report | 12 | SEC Filings | ||
13.05. | Galera Therapeutics: Galera Reports First Quarter 2024 Financial Results and Recent Corporate Updates | 215 | GlobeNewswire (Europe) | MALVERN, Pa., May 13, 2024 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel, proprietary therapeutics... ► Artikel lesen | |
03.05. | Galera Therapeutics: Galera Adopts Limited Duration Stockholder Rights Agreement | 262 | GlobeNewswire (Europe) | MALVERN, Pa., May 03, 2024 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a biopharmaceutical company focused on developing a pipeline of novel, proprietary therapeutics that have the... ► Artikel lesen | |
28.03. | Galera Therapeutics: Galera Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Updates | 240 | GlobeNewswire (Europe) | MALVERN, Pa., March 28, 2024 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a biopharmaceutical company focused on developing a pipeline of novel, proprietary therapeutics that have... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
EVOTEC | 9,910 | +0,05 % | KURSEXPLOSION bei Biotech-Aktie! BioNTech, Evotec, Nyxoah | Geht es bei Evotec jetzt doch ganz schnell? Ein Finanzinvestor positioniert sich jedenfalls für eine Übernahme und die Aktie schoss zuletzt kräftig nach oben. Ist damit die Enttäuschung über die Quartalszahlen... ► Artikel lesen | |
EPIGENOMICS | 0,900 | -21,74 % | EQS-AFR: Epigenomics AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß § 114, 115, 117 WpHG | EQS Vorabbekanntmachung Finanzberichte: Epigenomics AG
/ Vorabbekanntmachung über die Veröffentlichung von Rechnungslegungsberichten
Epigenomics AG: Vorabbekanntmachung über die... ► Artikel lesen | |
CORE ONE LABS | 0,079 | -100,00 % | New Core One 3D Printer From Prusa May Be the Answer to Its Bambu Problem | ||
CRISPR THERAPEUTICS | 44,900 | 0,00 % | CRISPR Therapeutics Stock Falls 7% in Two Weeks: Time to Hold or Sell? | ||
MAINZ BIOMED | 0,206 | -2,38 % | Mainz Biomed und Thermo Fisher Scientific unterzeichnen Kooperationsvereinbarung | ||
TREVENA | 0,153 | 0,00 % | Trevena Inc.: Trevena Reports Third Quarter 2024 Results and Provides Business Update | CHESTERBROOK, Pa., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with... ► Artikel lesen | |
DEFENCE THERAPEUTICS | 0,364 | -1,62 % | Defence Therapeutics Inc.: Defence Therapeutics Announces Securities for Debenture Financing | Vancouver, British Columbia--(Newsfile Corp. - November 14, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company... ► Artikel lesen | |
CENTOGENE | 0,070 | -1,41 % | Centogene NV: CENTOGENE Signs Strategic Transaction With Private Equity Group Charme Capital Partners | CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Centogene N.V. (OTC: CNTGF) ("CENTOGENE" or the "Company"), the essential life science partner for data-driven answers... ► Artikel lesen | |
GALAPAGOS NV | 23,840 | -0,83 % | GALAPAGOS NV - S-8, Securities to be offered to employees in employee benefit plans | ||
GINKGO BIOWORKS | 6,100 | +0,83 % | Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Sees Significant Drop in Short Interest | ||
NOVOCURE | 16,130 | +0,88 % | Novocure meldet Finanzergebnisse des dritten Quartals 2024 | Quartalsnettoumsatz von 155 Millionen USD, Steigerung von 22 gegenüber dem Vorjahr, mit rekordverdächtigen 4.113 aktiven Patienten in Therapie zum 30. September 2024 FDA genehmigt Optune Lua... ► Artikel lesen | |
CELLECTAR BIOSCIENCES | 1,480 | 0,00 % | Cellectar Biosciences, Inc.: Cellectar Biosciences Reports Financial Results for Q3 2024 and Provides a Corporate Update | Phase 2 CLOVER-WaM pivotal study data selected for oral presentation at 66th Annual American Society of Hematology Meeting and Exposition Raised approximately $19.4 million with potential to raise... ► Artikel lesen | |
SENSEI BIOTHERAPEUTICS | 0,462 | -0,43 % | Sensei Biotherapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights | - SNS-101 Phase 1/2 dose expansion clinical data expected in the first half of 2025 - - Organizational restructuring to focus resources on advancing the clinical development of SNS-101 - ... ► Artikel lesen | |
RECURSION PHARMACEUTICALS | 6,040 | 0,00 % | Recursion Pharmaceuticals, Inc.: Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery | Recursion unveils post-combination technology-enabled portfolio with more than 10 clinical and preclinical programs, 10 advanced discovery programs, and more than 10 partnered programsPlatform will... ► Artikel lesen | |
AC IMMUNE | 3,090 | +0,98 % | AC Immune stock jumps 20% on data for Parkinson's disease drug |